BACKGROUND: @entity644 is a marker of cardiovascular and @entity8 in @entity1 with @entity740 ( @entity740 ), and reduction in @entity644 has been associated with improved cardiovascular and renal outcomes. While active @entity560 and its analogs have been shown to have renal protective effects in animals, these hormones have not been shown to reduce @entity644 in @entity740 @entity1 . METHODS: In three double-blind, randomized, placebo-controlled studies to evaluate the safety and efficacy of oral @entity21453 , 220 @entity740 stage 3 and 4 @entity1 with @entity3528 ( @entity3528 ) were randomized to oral @entity21453 (N= 107, mean dose 9.5 microg/week) or placebo (N= 113) and followed for up to 24 weeks. In conjunction with other safety measures, @entity644 was measured by dipstick and read by an automated reader at the beginning and end of trial. We subsequently analyzed the dipstick data to evaluate the effect of @entity21453 on @entity644 . RESULTS: At baseline, @entity644 was present in 57 @entity1 randomized to oral @entity21453 and 61 @entity1 randomized to placebo (NS). At the final visit, 29/57 (51%) of the @entity21453 @entity1 compared to 15/61 (25%) placebo @entity1 had reduction in @entity644 , P= 0.004 (odds for reduction in @entity644 3.2 times greater for @entity21453 @entity1 , 95% CI 1.5-6.9). For the @entity1 who had both @entity644 at baseline and @entity461 ( @entity461 ) suppression (end point defined as 2 consecutive > or =30% decreases in iPTH from baseline), 27/51 (53%) @entity1 had a reduction in the @entity644 in the @entity21453 group and 0/7 (0%) had a reduction in @entity644 in the placebo group. Reduction of @entity644 favored @entity1 on @entity21453 , regardless of age, sex, race, @entity6 , @entity101 , or use of therapies to block the renin-angiotensin- @entity1369 system (RAAS). CONCLUSION: Our results demonstrate that the reduction in @entity644 was associated with @entity21453 treatment, and the reduction in @entity644 was independent of concomitant use of agents that block the RAAS. @entity21453 as a potential pharmacologic means of reducing @entity644 in @entity740 @entity1 warrants further investigation.

Antiproteinuric effect of oral XXXX in @entity740 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria', 'Proteinuria'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal disease'] @entity1369 :: ('MESH:D000450', 'Chemical') :: ['aldosterone'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity3528 :: ('MESH:D006962', 'Disease') :: ['secondary hyperparathyroidism', 'SHPT'] @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'chronic kidney disease'] @entity21453 :: ('MESH:C084656', 'Chemical') :: ['Paricalcitol', 'paricalcitol'] @entity461 :: ('5741', 'Gene') :: ['PTH', 'parathyroid hormone'] @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']
@entity21453 :: (MESH:C084656,Chemical) :: ['paricalcitol']
